Steven Cohen's DSGN Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 2.72 M shares of Design Therapeutics, Inc. (DSGN) worth $28.97 M, representing 0.04% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in DSGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 2.03 M shares. Largest reduction occurred in Q1 2026, reducing 2.65 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Design Therapeutics (DSGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Design Therapeutics (DSGN) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -2.65 M | Reduce 49.32% | 2.72 M | $10.64 |
| Q4 2025 | +2.03 M | Add 60.81% | 5.37 M | $9.38 |
| Q3 2025 | +1.53 M | Add 84.84% | 3.34 M | $7.53 |
| Q2 2025 | -10,640 | Reduce 0.59% | 1.81 M | $3.37 |
| Q1 2025 | -38,892 | Reduce 2.09% | 1.82 M | $3.86 |
| Q4 2024 | +256,010 | Add 15.99% | 1.86 M | $6.17 |
| Q3 2024 | +609,939 | Add 61.56% | 1.6 M | $5.38 |
| Q2 2024 | +397,285 | Add 66.94% | 990,801 | $3.35 |
| Q1 2024 | +593,516 | New Buy | 593,516 | $4.03 |
| Q4 2023 | -1 | Sold Out | 0 | $0.00 |
| Q3 2023 | -5,348 | Reduce 99.98% | 1 | $2.00 |
| Q2 2023 | -4,781 | Reduce 47.20% | 5,349 | $6.30 |
| Q1 2023 | +10,130 | New Buy | 10,130 | $5.77 |
Steven Cohen's Design Therapeutics Investment FAQs
Steven Cohen first purchased Design Therapeutics, Inc. (DSGN) in Q1 2023, acquiring 10,130 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Design Therapeutics, Inc. (DSGN) for 13 quarters since Q1 2023.
Steven Cohen's largest addition to Design Therapeutics, Inc. (DSGN) was in Q4 2025, adding 5,372,004 shares worth $50.39 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 2,722,754 shares of Design Therapeutics, Inc. (DSGN), valued at approximately $28.97 M.
As of the Q1 2026 filing, Design Therapeutics, Inc. (DSGN) represents approximately 0.04% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Design Therapeutics, Inc. (DSGN) was 5,372,004 shares, as reported at the end of Q4 2025.